Oruka Therapeutics lost $50 million last quarter and shared updates on its drug projects.

Nov 9, 2026, 7:28 PM ETResultsRead the original at globenewswire.com

Good for ORKA

Oruka has $1.2 billion in cash, positive Phase 2 results for ORKA-001, and plans Phase 3 trials in the first half of 2027. Its $50 million loss from higher costs tempers the news, but the drug progress and cash support a favorable reading.

ORKA · Oruka Therapeutics

AI read · Good for ORKA

The AI's read

The results give ORKA-001 a path toward larger tests, and progress on ORKA-002 and ORKA-004 adds support. Oruka plans to start Phase 3 tests in the first half of 2027. Higher research and office costs still caused a loss, but its cash can support continued drug testing.

Get alerts for ORKA

Follow Oruka Therapeutics (ORKA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ORKA

Free on the App Store and Google Play, or on the web.